PMID- 36006593
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230110
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 13
IP  - 10
DP  - 2022 Oct
TI  - Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with 
      Type 2 Diabetes in Treatment Intensification: A Retrospective Observational 
      Single-Center Study.
PG  - 1779-1788
LID - 10.1007/s13300-022-01313-0 [doi]
AB  - INTRODUCTION: Once-weekly (OW) glucagon-like peptide 1 receptor agonist (GLP-1RA) 
      semaglutide has been shown to have a more potent glycated hemoglobin 
      (HbA1c)-lowering effect than other oral hypoglycemic agents and existing GLP-1RAs 
      in global randomized controlled trials. The study aim was to evaluate the safety 
      and effectiveness of OW semaglutide in Japanese patients with type 2 diabetes 
      mellitus (T2DM) in a real-world clinical setting and identify pre- and 
      post-treatment predictors of good response. METHODS: We investigated the change 
      in HbA1c, percentage of patients achieving < 7% HbA1c, and factors contributing 
      to the effect 6 months after OW semaglutide use in Japanese patients with T2DM. 
      We also examined differences in effectiveness between patients with different 
      backgrounds. RESULTS: At baseline, the 77 patients had a mean baseline HbA1c of 
      8.1% +/- 1.23%, 74% of the patients were injecting another GLP-1RA, and 42.9% of 
      the patients were being treated with insulin. HbA1c decreased by 0.89% and by 
      0.66% in the other GLP-1RA users. The rate of achievement of < 7% HbA1c increased 
      from 21% to 43%. There were no differences in effect by age, sex, or body mass 
      index. Higher baseline HbA1c and shorter duration of diabetes were associated 
      with greater HbA1c reduction. OW semaglutide was tolerable for the majority of 
      our study population. CONCLUSION: This study provided real-world evidence showing 
      that OW semaglutide significantly reduced HbA1c in Japanese patients with T2DM 
      who had inadequate HbA1c control.
CI  - (c) 2022. The Author(s).
FAU - Yamada, Hodaka
AU  - Yamada H
AUID- ORCID: 0000-0002-1882-1814
AD  - Department of Medicine, Division of Endocrinology and Metabolism, Jichi Medical 
      University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama, 
      330-8503, Japan. hyamada0510@jichi.ac.jp.
FAU - Yoshida, Masashi
AU  - Yoshida M
AD  - Department of Medicine, Division of Endocrinology and Metabolism, Jichi Medical 
      University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama, 
      330-8503, Japan.
FAU - Suzuki, Daisuke
AU  - Suzuki D
AD  - Department of Medicine, Division of Endocrinology and Metabolism, Jichi Medical 
      University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama, 
      330-8503, Japan.
FAU - Funazaki, Shunsuke
AU  - Funazaki S
AD  - Department of Medicine, Division of Endocrinology and Metabolism, Jichi Medical 
      University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama, 
      330-8503, Japan.
FAU - Nagashima, Shuichi
AU  - Nagashima S
AD  - Department of Medicine, Division of Endocrinology and Metabolism, Jichi Medical 
      University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama, 
      330-8503, Japan.
FAU - Masahiko, Kimura
AU  - Masahiko K
AD  - Department of Pharmacy, Jichi Medical University Saitama Medical Center, 1-847 
      Amanuma-cho, Omiya-ku, Saitama, 330-8503, Japan.
FAU - Kiyoshi, Otsuka
AU  - Kiyoshi O
AD  - Department of Pharmacy, Jichi Medical University Saitama Medical Center, 1-847 
      Amanuma-cho, Omiya-ku, Saitama, 330-8503, Japan.
FAU - Hara, Kazuo
AU  - Hara K
AD  - Department of Medicine, Division of Endocrinology and Metabolism, Jichi Medical 
      University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama, 
      330-8503, Japan.
LA  - eng
GR  - 19K18012/JSPS KAKENHI/
GR  - 18K08525/JSPS KAKENHI/
PT  - Journal Article
DEP - 20220825
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
EIN - Diabetes Ther. 2023 Mar;14(3):619-620. PMID: 36627460
PMC - PMC9500122
OTO - NOTNLM
OT  - Glucagon-like peptide 1 receptor agonist
OT  - Once-weekly semaglutide
OT  - Real-world evidence
OT  - Type 2 diabetes mellitus
EDAT- 2022/08/26 06:00
MHDA- 2022/08/26 06:01
PMCR- 2022/08/25
CRDT- 2022/08/25 11:26
PHST- 2022/07/04 00:00 [received]
PHST- 2022/08/16 00:00 [accepted]
PHST- 2022/08/26 06:00 [pubmed]
PHST- 2022/08/26 06:01 [medline]
PHST- 2022/08/25 11:26 [entrez]
PHST- 2022/08/25 00:00 [pmc-release]
AID - 10.1007/s13300-022-01313-0 [pii]
AID - 1313 [pii]
AID - 10.1007/s13300-022-01313-0 [doi]
PST - ppublish
SO  - Diabetes Ther. 2022 Oct;13(10):1779-1788. doi: 10.1007/s13300-022-01313-0. Epub 
      2022 Aug 25.